These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis. Narajczyk M; Moskot M; Konieczna A Acta Biochim Pol; 2012; 59(4):693-6. PubMed ID: 23230565 [TBL] [Abstract][Full Text] [Related]
5. [Principles of therapeutic approaches for mucopolysaccharidoses]. Caillaud C Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383 [TBL] [Abstract][Full Text] [Related]
6. Substrate reduction therapies for mucopolysaccharidoses. Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626 [TBL] [Abstract][Full Text] [Related]
7. [Mucopolysaccharidoses--biochemical mechanisms of diseases and therapeutic possibilities]. Kloska A; Tylki-Szymańska A; Wegrzyn G Postepy Biochem; 2011; 57(2):133-47. PubMed ID: 21913414 [TBL] [Abstract][Full Text] [Related]
8. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. Jakóbkiewicz-Banecka J; Piotrowska E; Narajczyk M; Barańska S; Wegrzyn G J Biomed Sci; 2009 Mar; 16(1):26. PubMed ID: 19272193 [TBL] [Abstract][Full Text] [Related]
9. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms. Shapiro EG; Jones SA; Escolar ML Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036 [TBL] [Abstract][Full Text] [Related]
10. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia. Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724 [TBL] [Abstract][Full Text] [Related]
11. Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Węgrzyn G; Jakóbkiewicz-Banecka J; Narajczyk M; Wiśniewski A; Piotrowska E; Gabig-Cimińska M; Kloska A; Słomińska-Wojewódzka M; Korzon-Burakowska A; Węgrzyn A Med Hypotheses; 2010 Dec; 75(6):605-9. PubMed ID: 20732748 [TBL] [Abstract][Full Text] [Related]
12. Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Piotrowska E; Jakóbkiewicz-Banecka J; Tylki-Szymańska A; Czartoryska B; Wegrzyn A; Wegrzyn G Acta Paediatr; 2009 Apr; 98(4):743-9. PubMed ID: 19046346 [TBL] [Abstract][Full Text] [Related]
13. A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Wegrzyn G; Wegrzyn A; Tylki-Szymańska A Med Hypotheses; 2004; 62(6):986-92. PubMed ID: 15142662 [TBL] [Abstract][Full Text] [Related]
14. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Kakkis E; Marsden D Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020 [TBL] [Abstract][Full Text] [Related]
15. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Kim KH; Dodsworth C; Paras A; Burton BK Mol Genet Metab; 2013 Aug; 109(4):382-5. PubMed ID: 23845234 [TBL] [Abstract][Full Text] [Related]
16. Cell cycle disturbances in mucopolysaccharidoses: Transcriptomic and experimental studies on cellular models. Brokowska J; Gaffke L; Pierzynowska K; Cyske Z; Węgrzyn G Exp Biol Med (Maywood); 2022 Sep; 247(18):1639-1649. PubMed ID: 36000158 [TBL] [Abstract][Full Text] [Related]